User login
Key clinical point: Both probiotic and drug interventions decreased the persistence of irritable bowel syndrome (IBS) symptoms and abdominal pain scores compared with placebo in patients with IBS.
Major finding: Compared with placebo, both probiotic and drug interventions improved the persistence of IBS symptoms (relative risk [RR] 0.68; 95% CI 0.51-0.92, and RR 0.87; 95% CI 0.81-0.92, respectively) and abdominal pain scores (standardized mean difference [SMD] −0.35; 95% CI −0.56 to −0.14, and SMD −0.10; 95% CI −0.20 to 0.00, respectively).
Study details Findings are from a systematic review and meta-analysis of 32 randomized controlled trials including adults with IBS.
Disclosures: This study did not receive financial support. The authors declared being scientific advisory board members or serving as consultants for various sources.
Source: van der Geest AM et al. Comparing probiotic and drug interventions in irritable bowel syndrome: A meta-analysis of randomised controlled trials. Benef Microbes. 2022 (Jul 18). Doi: 10.3920/BM2021.0123
Key clinical point: Both probiotic and drug interventions decreased the persistence of irritable bowel syndrome (IBS) symptoms and abdominal pain scores compared with placebo in patients with IBS.
Major finding: Compared with placebo, both probiotic and drug interventions improved the persistence of IBS symptoms (relative risk [RR] 0.68; 95% CI 0.51-0.92, and RR 0.87; 95% CI 0.81-0.92, respectively) and abdominal pain scores (standardized mean difference [SMD] −0.35; 95% CI −0.56 to −0.14, and SMD −0.10; 95% CI −0.20 to 0.00, respectively).
Study details Findings are from a systematic review and meta-analysis of 32 randomized controlled trials including adults with IBS.
Disclosures: This study did not receive financial support. The authors declared being scientific advisory board members or serving as consultants for various sources.
Source: van der Geest AM et al. Comparing probiotic and drug interventions in irritable bowel syndrome: A meta-analysis of randomised controlled trials. Benef Microbes. 2022 (Jul 18). Doi: 10.3920/BM2021.0123
Key clinical point: Both probiotic and drug interventions decreased the persistence of irritable bowel syndrome (IBS) symptoms and abdominal pain scores compared with placebo in patients with IBS.
Major finding: Compared with placebo, both probiotic and drug interventions improved the persistence of IBS symptoms (relative risk [RR] 0.68; 95% CI 0.51-0.92, and RR 0.87; 95% CI 0.81-0.92, respectively) and abdominal pain scores (standardized mean difference [SMD] −0.35; 95% CI −0.56 to −0.14, and SMD −0.10; 95% CI −0.20 to 0.00, respectively).
Study details Findings are from a systematic review and meta-analysis of 32 randomized controlled trials including adults with IBS.
Disclosures: This study did not receive financial support. The authors declared being scientific advisory board members or serving as consultants for various sources.
Source: van der Geest AM et al. Comparing probiotic and drug interventions in irritable bowel syndrome: A meta-analysis of randomised controlled trials. Benef Microbes. 2022 (Jul 18). Doi: 10.3920/BM2021.0123